Abstract: Disclosed is a process for the conversion of acyclic C5 feedstock to a product comprising cyclic C5 compounds, such as, for example, cyclopentadiene, and catalyst compositions for use in such process. The process comprises the steps of contacting said feedstock and, optionally, hydrogen under acyclic C5 conversion conditions in the presence of a catalyst composition to form said product. The catalyst composition comprising a microporous crystalline aluminosilicate having a constraint index in the range of 3 to 12, a Group 10 metal, and, optionally, a Group 11 metal, in combination with a Group 1 alkali metal and/or a Group 2 alkaline earth metal.

Abstract: Disclosed is a process for the conversion of acyclic C5 feedstock to a product comprising cyclic C5 compounds, such as for example, cyclopentadiene, and catalyst compositions for use in such process. The process comprising the steps of contacting said feedstock and, optionally, hydrogen under acyclic C5 conversion conditions in the presence of a catalyst composition to form said product. The catalyst composition comprising a microporous crystalline ferrosilicate, a Group 10 metal, and, optionally, a Group 11 metal, in combination with an optional Group 1 alkali metal and/or an optional Group 2 alkaline earth metal.

Abstract: This invention relates to a process for converting acyclic C5 hydrocarbons to cyclopentadiene including: providing to the at least one adiabatic reaction zone a feedstock comprising acyclic C5 hydrocarbons at a temperature, T1, wherein the at least one adiabatic reaction zone comprises a first particulate material comprising catalyst material; contacting the feedstock and the first particulate material in the at least one adiabatic reaction zone under reaction conditions to convert at least a portion of the acyclic C5 hydrocarbons to a first effluent comprising cyclopentadiene intermediates, unconverted acyclic C5 hydrocarbons, and, optionally, cyclopentadiene; heating the first effluent to a temperature, T2; providing the first effluent to the at least one diabatic reaction zone; and contacting the first effluent and a second particulate material comprising catalyst material in the at least one diabatic reaction zone under reaction conditions to convert at least a portion of the cyclopentadiene intermediates

Abstract: The present application relates to an apparatus and method for purifying cumene. The apparatus and method for purifying cumene according to the present application can reduce the amount of energy consumption which occurs during purification processes and can provide an apparatus and method capable of efficiently purifying cumene.

Abstract: A process for removing one or more undesired (hydro)halocarbon compounds containing a ?CF2 moiety from a (hydro)fluoroalkene that does not contain a ?CF2 moiety, the process comprising contacting a composition comprising the (hydro)fluoroalkene and one or more undesired (hydro)halocarbon compounds with an aluminum-containing absorbent, activated carbon, or a mixture thereof, wherein the or each undesired (hydro)halocarbon compound is present in an amount of from about 0.1 to about 1000 ppm, based on the weight of the composition comprising the R-1234yf and one or more undesired (hydro)halocarbon compounds.

Abstract: Disclosed herein are methods for synthesizing 1,2,5,6-hexanetetrol (HTO), 1,6 hexanediol (HDO) and other reduced polyols from C5 and C6 sugar alcohols or R glycosides. The methods include contacting the sugar alcohol or R-glycoside with a copper catalyst, most desirably a Raney copper catalyst with hydrogen for a time, temperature and pressure sufficient to form reduced polyols having 2 to 3 fewer hydoxy groups than the starting material. When the starting compound is a C6 sugar alcohol such as sorbitol or R-glycoside of a C6 sugar such as methyl glucoside, the predominant product is HTO. The same catalyst can be used to further reduce the HTO to HDO.

Abstract: A method for producing catalysts containing copper, in particular for producing catalyst moldings having increased mechanical strength and low volume reduction, to the catalysts produced by means of the method according to the invention, and to the use of said catalysts as catalysts or as precursors and components for catalysts. The catalysts are suitable in particular for the synthesis of methanol and for the low-temperature conversion of CO into CO2.

Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.

Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostrate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: The present technology relates to methods of hydroformylating allyl alcohol to 4-hydroxybutanal and 2-methyl-3-hydroxypropanal, comprising (i) admixing allyl alcohol with CO and H2 to form a starting material mixture, and (ii) reacting the starting material mixture in the presence of a catalyst under conditions capable of forming a product mixture comprising 4-hydroxybutanal and 2-methyl-3-hydroxypropanal, wherein the catalyst is a transition metal complex comprising a transition metal ion and a diphosphine ligand with a bite angle from about 70° to about 100°, and wherein the ratio of 4-hydroxybutanal to 2-methyl-3-hydroxypropanal in the product mixture is less than 1.5:1.

Abstract: This disclosure provides, molecular metal catalysts supported by sterically bulky ?-diketonate (acac) ligands. Disclosed herein are bulky ?-diketonate ligands, methods of making bulky ?-diketonate ligands, and methods of making metal catalysts supported by sterically bulky ?-diketonate (acac) ligands.

Abstract: A catalytic dehydration-hydrolysis process for the co-production of acetic acid and dimethyl ether from a mixture of methanol and methyl acetate and water in which the amount of water fed to the process is controlled by the steps of dehydrating a methanol feed to provide a crude product comprising dimethyl ether, unconverted methanol and water; recovering therefrom a stream comprising dimethyl ether, water and methanol and a water stream; separating dimethyl ether from the dimethyl-ether containing stream to produce a methanol stream comprising methanol and water; and supplying to the dehydration-hydrolysis process at least part of the methanol stream and methyl acetate.

Abstract: A process to prepare a compound of Formula (I) wherein R3, R4 and R5 are each selected independently from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxyl, and wherein the alkyl, alkenyl, alkynyl, and alkoxyl may be optionally substituted with one or more halogen, alkyl, alkenyl, alkynyl, and alkoxyl.

Abstract: This invention relates to a process for obtaining highly pure aliphatic dialkyl esters of saturated dicarboxylic acids from vegetable oils, which can advantageously be used in polymerisation. The process comprises the steps of reacting with an aliphatic alcohol a triglycerides mixture containing at least one triglyceride of at least one saturated dicarboxylic acid in the presence of one or more catalysts capable of catalysing the esterification and transesterification reactions, and separating the dialkyl esters of saturated dicarboxylic acids from the reaction mixture thus obtained.

Abstract: Certain embodiments of the invention provide a method comprising treating a hydroxy-carboxylic acid compound with a compound of formula (I) in the absence of a solvent, to provide a diacid of formula (II), wherein R is a linker molecule; wherein each Y is independently a leaving group; and wherein X is a residue of a biologically active compound.

Abstract: The present application relates to amorfrutin analogs and uses as PPAR modulators for the treatment of metabolic syndrome, obesity, hyperlipidemia, elevated fasting blood glucose, elevated blood pressure, low HDL cholesterol, type 2 diabetes, cardiovascular disease, a neurodegenerative disease, malaria or irritable bowel syndrome.

Abstract: The invention relates to a compound of general formula (I) wherein: R1 is a hydrogen atom or a C1 to C4 alkyl radical; R2 is a C1 to C4 hydroxyl or alkoxyl radical; and R3 and R4 are independently a hydrogen atom or a C1 à C4 alkyl radical; and the enantiomers and mixtures of enantiomers thereof, especially in a racemic form.

Abstract: A compound of the general formula (I) A cosmetic composition including such a compound and its use as a deodorant.

Abstract: A one-to-many parallelized millireactor system capable of high throughput production in millireactors. Also disclosed is a method for carrying out multi-phase reactions.

Abstract: A method for producing an azido-amine derivative includes obtaining an azido-amine derivative and extracting the azido-amine derivative obtained by using an aromatic solvent or an ether solvent.

Abstract: The invention relates to a method for preparing cadaverine comprising: (1) obtaining an aqueous cadaverine salt composition from a fermentation system; (2) adjusting the pH of the aqueous cadaverine salt composition to a pH of at least about 12 by adding an inorganic base composition to provide a first composition comprising an aqueous cadaverine composition having a pH of at least about 12 and a solid composition comprising one or more alkali metal sulfates; (3) subjecting the first composition to solid-liquid separation without organic solvent extraction to provide the aqueous cadaverine composition and the solid composition; (4) distilling or evaporating the aqueous cadaverine composition of step (3) without organic solvent extraction to provide purified cadaverine; (5) preparing a saturated solution of the alkali metal sulfate(s) from the solid composition of step (3) at a temperature of about 35-40° C.

Abstract: Systems and methods for producing a colorless triethanolamine product stream with a degree of purity of greater than or equal to 99% by weight from the triethanolamine distillation columns in a non-reactive distillation process. The desired triethanolamine product stream can be obtained by increasing the bottom stream flow rate at the diethanolamine column by 80 kilograms per hour, and reducing the triethanolamine product stream flow rate by 500 kilograms per hour. This process can result in a reduction of the temperature at the triethanolamine column by up to 23.5 degrees. The reduced temperature can result in a triethanolamine product stream with an APHA color of 0 to less than 50, for example, 0 to 40, for example, 0 to 30, for example 0 to 20, and for example, 0 to 10.

Abstract: A method for the stabilization of an aqueous choline hydroxide solution includes, optionally adding a first stabilizer of a dithionite salt and/or a dialkylhydroxylamine to an aqueous solution containing reactants that will produce an aqueous choline hydroxide solution; and after the aqueous choline hydroxide solution is formed, adding a second stabilizer which comprises a dialkylhydroxylamine to the aqueous choline hydroxide solution. The stabilized choline hydroxide solution may include choline hydroxide, water, and a dialkylhydroxylamine and optionally a dithionite salt as a stabilizer present in an amount of from about 50 ppm to less than about 5000 ppm by weight relative to the total weight of the stabilized choline hydroxide solution.

Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

Abstract: A method for preparing an iminodisuccinate chelating agent, wherein a reaction comprising raw material A, raw material B, an alkali metal hydroxide, and water is carried out under ambient pressure, and at a pH in the range of 6-12 and a reaction temperature ranging from 65° C. to a boiling reflux temperature, and the mixed liquid obtained after the reaction is a mixture containing the iminodisuccinate chelating agent. The raw material A is a compound capable of obtaining a maleate through alkaline hydrolysis; and the raw material B is a compound capable of obtaining an aspartic acid through alkaline hydrolysis. With mild reaction conditions, a short reaction time and a high reaction yield, the preparation method is able to shorten the production process, improve the production efficiency, and reduce the production cost, and it is truly a preparation method which is highly efficient, environmentally friendly, and extremely suitable for industrial scale production.

Abstract: A method of making an amino acid triisocyanate is provided, the method comprising reacting an amino acid trihydrochloride with phosgene to form the amino acid triisocyanate. In some embodiments, the amino acid trihydrochloride comprises lysine ester trihydrochloride salt and the amino acid triisocyanate comprises lysine ester triisocyanate. In some embodiments, there is a lysine ester triisocyanate having a purity of at least about 98%, the lysine ester triisocyanate having a structure resulting from reacting lysine ester trihydrochloride salt with phosgene to form the lysine ester triisocyanate. These lysine ester triisocyanates can be used to make biodegradable polyurethanes.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: A peroxide solution of organic peroxide in an organic solvent, including at least one peroxide in a solvent, the solvent having a hydrophobic alcohol wherein the main carbonated chain having the alcohol function includes at least six carbon atoms, the solution also including a second, hydrophilic alcohol solvent representing a maximum of 15% wt. % of the solution. Also, a thermohardenable composition including said solution, and a method and a use relating to the composition.

Abstract: Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydration, ester group reduction, hydroxyl group protection, addition with imine after condensation with a chiral auxiliary, cyclization and deprotection to obtain the compound represented by formula (I). The present invention has advantages of easily available raw material, a few synthetic steps, simple operation, high yield, good stereoselectivity and low cost, and can be used for industrial production.

Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Abstract: The present invention relates to a 3-aryl-4 catechol-pyrrole-n-propanol compound and the derivatives thereof having General Formula (I), wherein:—R1 is an aryl group, particularly a phenyl, optionally substituted by one or more (C1-C2)alkyl groups one or more halogens, one or more —OH, —CN or CF3 groups, or a combination of same, and—R2 is a (C1-C2)alkyl group, a hydroxy(C1-C8)alkyl group, a (C1-C4)alocoxy(C1-C8)alkyl group, or a pharmaceutically acceptable hydrate or solvate of same. The invention also relates to the methods for preparing said compound and derivatives, to the pharmaceutical compositions containing same, and to the use of same as a drug or in the form of a prodrug converted via dimerization, particularly via oxidative coupling in the presence of a superoxide anion, in the treatment of cancer and diseases related to excessive angiogenesis.

Abstract: The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.

Abstract: This invention provides compounds of Formula (II), or (IIa) and or salts thereof, pharmaceutical compositions comprising a compound of Formula (II), or (IIa) and a pharmaceutically acceptable excipient, processes for making compounds for Formula (II), or (IIa) and intermediates useful in the preparation of same; and methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type II diabetes related disorders or diseases, anemia, depression, and renal disease) using compounds of Formula (I), (II), or (IIa).

Abstract: Provided is a production method of a synthetic intermediate for a heterocyclic compound having a renin inhibitory activity and useful as a prophylactic or therapeutic drug for diabetic nephropathy, hypertension and the like. A production method of a compound represented by the formula (III-1a), the formula (III-1b), the formula (III-1c) and/or the formula (III-1d); wherein each symbol is as described in DESCRIPTION, or a salt thereof, including reacting a compound represented by the formula (Ia) or (Ib): wherein each symbol is as described in DESCRIPTION, or a salt thereof with a compound represented by the formula (II): wherein each symbol is as described in DESCRIPTION, or a salt thereof, in the presence of an aluminum compound and a chiral amine compound.

Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Abstract: The present invention provides: a method for producing a mixed sulfonic acid anhydride of the general formula (1) by reacting a sulfonic acid compound of the general formula (2) with a perfluoroalkyl sulfonic acid anhydride or a perfluoroalkyl sulfonic acid halide; and a method for producing a sulfonamide compound of the general formula (4) obtained by reacting an amine compound of the general formula (3) with a mixed sulfonic acid anhydride of the general formula (1).

Abstract: The present disclosure provides a method for preparing a caprolactam and the method includes steps of subjecting cyclohexanone oxime and sulfuric acid to a Beckmann rearrangement reaction to obtain a rearrangement mixture; neutralizing the rearrangement mixture and extracting the neutralized rearrangement mixture using an organic solvent sequentially; and subjecting the extracted organic solution to a hydrogenation reaction so as to simplify the process to produce a high quality caprolactam.

Abstract: An improved oxidation process for preparing 5-amino-3-cyano-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylsulphinyl-pyrazole, of formula (I) is described. The process includes admixing 5-amino-3-cyano-1-(2, 6-dichloro-4-trifluoromethylphenyl)-4-trifluoromethylthiopyrazole of formula (II) with dichloroacetic acid and hydrogen peroxide in the presence of a strong acid.

Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Abstract: This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted C1-6alkyloxyC1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(?O)pR6, —NH—S(?O)pR6, —C(?O)R6, —NHC(?O)H, —C(?O)NHNH2, —NHC(?O)R6, —C(?NH)R6 or a 5-membered heterocycle; X1 is —NR5—, —NH—NH—, —N?N—, —O—, —C(?O)—, C1-4alkanediyl,

Abstract: A crystalline form of metsulfuron-methyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.

Abstract: A crystalline form of iodosulfuron-methyl-sodium of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.

Abstract: Described herein is the LPA1 antagonist 1-{4?-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions.

Abstract: Embodiments of the present disclosure provide for compositions including a compound, pharmaceutical compositions including the compound, methods of treatment of a disease or related condition (e.g., neurological disease on condition), methods of treatment using compositions or pharmaceutical compositions, and the like.

Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.

Abstract: A composition of monoanhydro-hexitol monoalkyl ether isomers bearing an alkyl ether radical (OR) at C-3, C-5 or C-6 of the monoanhydro-hexitol, in which the alkyl group (R) is a linear or branched, cyclic or noncyclic hydrocarbon-based group comprising between 4 to 18 carbon atoms, the process for obtaining such a composition and the use thereof as a nonionic surfactant, emulsifier, lubricant, antimicrobial agent or dispersant.

Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

Abstract: A process for fluorination of aromatic compounds employing iodonium ylides and applicable to radiofluorination using 18F is described. Processes, intermediates, reagents and radiolabelled compounds are described.

Abstract: The present invention describes the crystalline form of imazapyr of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation. The invention also describes the use of various solvents towards the crystalline form preparation conditions.

Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.